Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

661. The discovery of insulin: the Rochester, New York, connection. (Abstract)

The discovery of insulin: the Rochester, New York, connection. The discovery of insulin in Toronto by Dr. Frederick G. Banting and colleagues has been well chronicled. The story of how insulin therapy was introduced into the United States has been less detailed. The first patient to be treated with insulin in the United States resided in Rochester, New York, a city with a then newly developed medical school that had also tried to recruit Dr. Banting. A series of letters from that period (...) provides a description of the course of a juvenile patient with diabetes before and after the use of insulin as a therapeutic agent.

2005 Annals of Internal Medicine

662. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Full Text available with Trip Pro

Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Obesity, diabetes mellitus, and glucose intolerance have been associated with increased pancreatic cancer risk; however, prediagnostic serum insulin concentration has not been evaluated as a predictor of this malignancy.To investigate whether prediagnostic fasting glucose and insulin concentrations and insulin resistance are associated with subsequent incidence of exocrine pancreatic cancer in a cohort of male (...) Registry.After adjusting for age, smoking, and body mass index, higher baseline fasting serum concentrations of glucose, insulin, and insulin resistance were positively associated with pancreatic cancer. The presence of biochemically defined diabetes mellitus (glucose, > or =126 mg/dL [> or =6.99 mmol/L]) and insulin concentration in the highest vs lowest quartile both showed a significant 2-fold increased risk (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.04-4.35; and HR, 2.01; 95% CI, 1.03-3.93

2005 JAMA

663. Association of socioeconomic position with insulin resistance among children from Denmark, Estonia, and Portugal: cross sectional study. Full Text available with Trip Pro

Association of socioeconomic position with insulin resistance among children from Denmark, Estonia, and Portugal: cross sectional study. To examine the association between socioeconomic position and insulin resistance in children from three countries in northern Europe (Denmark), eastern Europe (Estonia), and southern Europe (Portugal) that have different physical, economic, and cultural environments.Cross sectional study.3189 randomly selected schoolchildren aged 9 and 15 years from Denmark (n (...) = 933), Estonia (n = 1103), and Portugal (n = 1153).Insulin resistance (homoeostasis model assessment).Family income and parental education were inversely associated with insulin resistance in Danish children but were positively associated with insulin resistance in Estonian and Portuguese children. Among Danish children, insulin resistance was 24% lower (95% confidence interval -38% to -10%) in those whose fathers had the most education compared with those with the least education. The equivalent

2005 BMJ

664. Insulin and oral agents for managing cystic fibrosis-related diabetes. (Abstract)

Insulin and oral agents for managing cystic fibrosis-related diabetes. Insulin therapy is recommended by the Cystic Fibrosis Foundation when cystic fibrosis-related diabetes has been diagnosed. Diagnosis is based on an elevated fasting blood glucose level greater than 6.94 mmol/liter (125 mg/deciliter) or symptomatic diabetes for random glucose levels greater than 11.11 mmol/liter (200 mg/deciliter).To examine the evidence that, when treated with agents for managing diabetes, people with cystic (...) , a condition which complicates the course of cystic fibrosis, insulin therapy is the recommended and most widely used treatment method. Lung function has been reported to improve with the use of insulin, but this has not been correlated to the degree in which sugar metabolism has been affected. While the Cystic Fibrosis Foundation recommends insulin therapy be used in managing diabetes, this systematic review identifies the need for a multicentre randomized controlled trial assessing both the efficacy

2005 Cochrane

665. Insulin resistance and risk of congestive heart failure. Full Text available with Trip Pro

Insulin resistance and risk of congestive heart failure. Diabetes and obesity are established risk factors for congestive heart failure (CHF) and are both associated with insulin resistance.To explore if insulin resistance may predict CHF and may provide the link between obesity and CHF.The Uppsala Longitudinal Study of Adult Men, a prospective, community-based, observational cohort in Uppsala, Sweden. We investigated 1187 elderly (>or=70 years) men free from CHF and valvular disease (...) at baseline between 1990 and 1995, with follow-up until the end of 2002. Variables reflecting insulin sensitivity (including euglycemic insulin clamp glucose disposal rate) and obesity were analyzed together with established risk factors (prior myocardial infarction, hypertension, diabetes, electrocardiographic left ventricular hypertrophy, smoking, and serum cholesterol level) as predictors of subsequent incidence of CHF, using Cox proportional hazards analyses.First hospitalization for heart failure.One

2005 JAMA

666. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. (Abstract)

Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. It is not known how a low-carbohydrate, high-protein, high-fat diet causes weight loss or how it affects blood glucose levels in patients with type 2 diabetes.To determine effects of a strict low-carbohydrate diet on body weight, body water, energy intake and expenditure, glycemic control, insulin sensitivity, and lipid levels in obese patients with type 2 (...) diabetes.Inpatient comparison of 2 diets.General clinical research center of a university hospital.10 obese patients with type 2 diabetes.Usual diets for 7 days followed by a low-carbohydrate diet for 14 days.Body weight, water, and composition; energy intake and expenditure; diet satisfaction; hemoglobin A1c; insulin sensitivity; 24-hour urinary ketone excretion; and plasma profiles of glucose, insulin, leptin, and ghrelin.On the low-carbohydrate diet, mean energy intake decreased from 3111 kcal/d to 2164 kcal

2005 Annals of Internal Medicine

667. [Permanent changes in insulin resistance by changes in life style among subjects with impaired glucose tolerance]. (Abstract)

[Permanent changes in insulin resistance by changes in life style among subjects with impaired glucose tolerance]. 15293711 2005 01 25 2015 11 19 0012-7183 120 12 2004 Duodecim; laaketieteellinen aikakauskirja Duodecim [Permanent changes in insulin resistance by changes in life style among subjects with impaired glucose tolerance]. 1495-7 Uusitupa Matti M Kliinisen ravitsemustieteen laitos ja Elintarvikkeiden terveysvaikutusten tutkimuskeskus, Kuopion yliopisto. matti.uusitupa@uku.fi Lindi (...) Test Humans Insulin Resistance Life Style Male Reference Values Risk Assessment Severity of Illness Index Treatment Outcome 2004 8 6 5 0 2005 1 26 9 0 2004 8 6 5 0 ppublish 15293711

2005 Duodecim; laaketieteellinen aikakauskirja Controlled trial quality: uncertain

668. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Full Text available with Trip Pro

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial (...) with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3).In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly assigned to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp-induced C-peptide release before and after the administration of glucagon.At 6, 12, and 18 months, residual beta-cell

2005 NEJM Controlled trial quality: uncertain

669. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Full Text available with Trip Pro

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine

2005 JAMA Controlled trial quality: predicted high

670. Apidra (insulin glulisine)

Apidra (insulin glulisine) 1/38 ?EMEA 2005 SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Apidra. For information on changes after approval please refer to module 8. 1. Introduction This is a complete application for a marketing authorisation for the medicinal product Apidra submitted in accordance with Article 8.3 (i) of Directive 2001/83/EEC. Apidra contains the new active substance insulin glulisine, an analogue of human insulin. Insulin (...) glulisine is produced by recombinant DNA technology in Escherichia coli (E. coli) and differs from human insulin by two amino acid substitutions on the B chain of the protein. These give insulin glulisine a faster onset of action as they prevent the formation of inactive hexamers when injected. Insulins have a pronounced tendency to form hexamers that need to disintegrate to dimers and monomers to be pharmacologically active. The amino acid substitutions in insulin glulisine destabilise the hexamers

2005 European Medicines Agency - EPARs

671. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review

Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Innes K E, Bourguignon C, Taylor A G CRD summary The review determined (...) the efficacy of yoga on anthropometric and physiologic indices of cardiovascular disease risk and related end points. Based on a large number of diverse primary studies of limited quality, the authors are justified in concluding that further well-conducted research is necessary. Authors' objectives To determine the efficacy of yoga on anthropometric and physiologic indices (such as insulin resistance syndrome, IRS) of cardiovascular disease (CVD) risk and on related end points. Searching MEDLINE, IndMED

2005 DARE.

672. Biphasic insulin aspart 30: literature review of adverse events associated with treatment

Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R CRD summary This review assessed the safety of biphasic insulin aspart 30 (BIAsp 30) for patients with diabetes. The authors concluded that the safety profile is comparable (...) to that of biphasic human insulin 30 (BHI 30) and neutral protamine Hagedorn (NPH) insulin, and that the risk of major and nocturnal hypoglycaemia is lower. Poor reporting and problems with review methodology mean that the reliability of these conclusions should be regarded with great caution. Authors' objectives To assess the safety of biphasic insulin aspart 30 (BIAsp 30), compared with alternative insulin products, in patients with type 1 or type 2 diabetes. Searching MEDLINE was searched to February 2005

2005 DARE.

673. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin (...) glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Valentine W J, Palmer A J, Lammert M, Nicklasson L, Foos V, Roze S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of biphasic

2005 NHS Economic Evaluation Database.

674. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Roze S, Valentine W J, Zakrzewska K E, Palmer A J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study evaluated the use of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) for the treatment of patients with Type 1 diabetes. Type

2005 NHS Economic Evaluation Database.

675. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Lechleitner M, Roden M, Haehling E (...) , Mueller M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of insulin glargine (IG) in combination with oral antidiabetic drugs (OADs) for the treatment of patients with Type 2 diabetes mellitus. Type of intervention Treatment

2005 NHS Economic Evaluation Database.

676. Breath test for detection of insulin resistance (Diatest TM)

Breath test for detection of insulin resistance (Diatest TM) Breath test for detection of insulin resistance (Diatest TM) Breath test for detection of insulin resistance (Diatest TM) Topfer L-A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Topfer L-A. Breath test for detection of insulin resistance (Diatest TM) Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this study is to review the available information on the breath test for the detection of insulin resistance (Diatest TM) manufactured by Isodiagnostika Inc, Edmonton, AB. Authors' conclusions Breath tests are non-invasive, easily administered and more acceptable to patients than either blood or urine tests. Larger studies are needed to determine whether patients will benefit from the measurement of insulin

2005 Health Technology Assessment (HTA) Database.

677. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 - 2004)

Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 - 2004) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

678. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Bullano M F, Al-Zakwani I S, Fisher M D, Menditto (...) L, Willey V J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two insulin products for the treatment of patients with Type 1 or Type 2 diabetes were examined. One was the intermediate-acting insulin analogue neutral protamine

2005 NHS Economic Evaluation Database.

679. Diatest: point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes

Diatest: point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes National Horizon Scanning Unit Horizon scanning prioritising summary Volume 10, Number 3: Diatest ™ : Point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes. September 2005 © Commonwealth of Australia 2005 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining (...) summary was prepared by Adriana Parrella, Janet Hiller and Linda Mundy from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Department of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005. PRIORITISING SUMMARY REGISTER ID: 000172 NAME OF TECHNOLOGY: DIATEST ™ PURPOSE AND TARGET GROUP: POINT-OF-CARE DIAGNOSTIC TEST FOR DETECTION OF INSULIN RESISTANCE IN PATIENTS AT RISK OF TYPE 2 DIABETES. STAGE OF DEVELOPMENT (IN AUSTRALIA): ? Yet to emerge

2005 Australia and New Zealand Horizon Scanning Network

680. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. (Abstract)

Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Rising demand for islet transplantation will lead to severe donor shortage in the near future, especially in countries where cadaveric organ donation is scarce. We undertook a successful transplantation of living-donor islets for unstable diabetes. The recipient was a 27-year-old woman who had had brittle, insulin-dependent diabetes mellitus for 12 years. The donor, who was a healthy 56-year-old woman (...) and mother of the recipient, underwent a distal pancreatectomy. After isolation, 408 114 islet equivalents were transplanted immediately. The transplants functioned immediately and the recipient became insulin-independent 22 days after the operation. The donor had no complications and both women showed healthy glucose tolerance. Transplantation of living-donor islets from the distal pancreas can be sufficient to reverse brittle diabetes.

2005 Lancet